Auswahl der wissenschaftlichen Literatur zum Thema „MiR-3192-5p“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Inhaltsverzeichnis
Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "MiR-3192-5p" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Zeitschriftenartikel zum Thema "MiR-3192-5p"
You, Qi, Yuan Yao, Jinyu Wu, Congcong Cheng, Yunxiu Li und Haitao Yuan. „YY1-induced lncRNA DSCR8 promotes the progression of ovarian cancer via miR-3192-5p/YY1 axis“. Biomedicine & Pharmacotherapy 129 (September 2020): 110339. http://dx.doi.org/10.1016/j.biopha.2020.110339.
Der volle Inhalt der QuelleYou, Qi, Yuan Yao, Jinyu Wu, Congcong Cheng, Yunxiu Li und Haitao Yuan. „Retraction notice to "YY1-induced lncRNA DSCR8 promotes the progression of ovarian cancer via miR-3192-5p/YY1 axis"“. Biomedicine & Pharmacotherapy 141 (September 2021): 111986. http://dx.doi.org/10.1016/j.biopha.2021.111986.
Der volle Inhalt der QuelleMcLaughlin, Tracey, Ingela Schnittger, Anna Nagy, Elizabeth Zanley, Yue Xu, Yanqiu Song, Koen Nieman et al. „Relationship Between Coronary Atheroma, Epicardial Adipose Tissue Inflammation, and Adipocyte Differentiation Across the Human Myocardial Bridge“. Journal of the American Heart Association 10, Nr. 22 (16.11.2021). http://dx.doi.org/10.1161/jaha.121.021003.
Der volle Inhalt der QuelleHAN LEE, WAI, BENJAMIN NELSON, APRIL M. TEAGUE, KEVIN R. SHORT und JEANIE B. TRYGGESTAD. „1174-P: Circulating MicroRNA in Youth with Type 1 Diabetes in Response to a Meal Challenge“. Diabetes 73, Supplement_1 (14.06.2024). http://dx.doi.org/10.2337/db24-1174-p.
Der volle Inhalt der QuelleDissertationen zum Thema "MiR-3192-5p"
Brochen, Célia. „Caractérisation des cibles de miARNs sensibilisateurs à l'action de la chimiothérapie en vue de la proposition de nouvelles stratégies thérapeutiques dans les cancers de l'ovaire (SensimiRs)“. Electronic Thesis or Diss., Normandie, 2024. http://www.theses.fr/2024NORMC401.
Der volle Inhalt der QuelleAlthough the majority of ovarian cancer patients initially respond to platinum-based chemotherapy, most of them relapse and develop chemoresistance, leading to poor 5-year survival. In this context, it is important to understand the molecular mechanisms involved in chemoresistance in order to develop new therapeutic approaches. In this context, a functional screening of a miRNA library identified several microRNAs (miRNAs) that sensitize two chemoresistant ovarian cancer lines (IGROV1-R10 and SKOV3) to the action of cisplatin, including miR-3192-5p, which induces massive cell death by apoptosis and has never been previously studied. The chemosensitizing effect of this miRNA was then validated on a third chemoresistant ovarian cancer line (OAW42-R). Using an approach combining bioinformatics and functional study, we observed that miR-3192-5p modulates the expression of several proteins involved in DNA damage response and repair mechanisms. Among these targets, we have demonstrated that the ERCC1 protein is a key determinant of the chemosensitizing effect of miR-3192-5p in the IGROV1-R10 and OAW42-R ovarian cancer lines. Preliminary results show that sensitization of SKOV3 cells to cisplatin action may be related to inhibition of CHEK1, whose expression is decreased in response to miR-3192-5p. In summary, this work has enabled us to identify new miRNAs involved in chemoresistance in ovarian cancers, and to characterize more precisely the role of miR-3192-5p and certain targets involved in its chemosensitizing action, opening the way to the proposal of new therapeutic strategies to improve the management of these cancers